User:Mr. Ibrahem/Maribavir

Mr. Ibrahem/Maribavir
Clinical data
Trade names	Livtencity
Other names	1263W94
AHFS/Drugs.com	Monograph
License data	US DailyMed: Maribavir;
Routes of; administration	By mouth
Legal status
Legal status	CA: ℞-only; US: ℞-only;
Identifiers
	IUPAC name (2S,3S,4R,5S)-2-[5,6-Dichloro-2-(propan-2-ylamino)benzimidazol-1-yl]-5-(hydroxymethyl)oxolane-3,4-diol;
Chemical and physical data
Formula	C15H19Cl2N3O4
Molar mass	376.23 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)Nc1nc2cc(c(cc2n1[C@@H]3[C@H]([C@H]([C@@H](O3)CO)O)O)Cl)Cl;
	InChI InChI=1S/C15H19Cl2N3O4/c1-6(2)18-15-19-9-3-7(16)8(17)4-10(9)20(15)14-13(23)12(22)11(5-21)24-14/h3-4,6,11-14,21-23H,5H2,1-2H3,(H,18,19)/t11-,12-,13-,14-/m0/s1 ; Key:KJFBVJALEQWJBS-XUXIUFHCSA-N ;
	(what is this?) (verify)

Maribavir, sold under the brand name Livtencity, is an antiviral medication used to treat post-transplant cytomegalovirus (CMV).^[2] Specifically it is used in cases where ganciclovir, valganciclovir, cidofovir, and foscarnet are not effective.^[2] It is taken by mouth.^[2]

Common side effects include taste disturbance, nausea, diarrhea, vomiting, and fatigue.^[2] Safety in pregnancy is unclear.^[2] It is a cytomegalovirus pUL97 kinase inhibitor thus blocks virus replication.^[2]^[3]

Maribavir was approved for medical use in the United States in 2021.^[2] As of 2022 it has been recommended for approval in Europe.^[4] In the United States 4 weeks costs about 25,000 USD as of 2022.^[5]

References[edit]

^ https://pdf.hres.ca/dpd_pm/00067349.PDF Archived 1 October 2022 at the Wayback Machine ^{[bare URL PDF]}
^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k "Livtencity- maribavir tablet, coated". DailyMed. Archived from the original on 19 December 2021. Retrieved 19 December 2021.
^ ^a ^b "FDA Approves First Treatment for Common Type of Post-Transplant Infection that is Resistant to Other Drugs". U.S. Food and Drug Administration (FDA) (Press release). 23 November 2021. Archived from the original on 24 November 2021. Retrieved 23 November 2021. This article incorporates text from this source, which is in the public domain.
^ "Maribavir". SPS - Specialist Pharmacy Service. 18 January 2017. Archived from the original on 5 March 2022. Retrieved 24 October 2022.
^ "Maribavir". Goodrx. Archived from the original on 24 October 2022. Retrieved 24 October 2022.

[1] ttps://pdf.hres.ca/dpd_pm/00067349.PDF Archived 1 October 2022 at the Wayback Machine ^{[bare URL PDF]}

[PI2022-2] ^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k "Livtencity- maribavir tablet, coated". DailyMed. Archived from the original on 19 December 2021. Retrieved 19 December 2021.

[FDA2022PR-3] "FDA Approves First Treatment for Common Type of Post-Transplant Infection that is Resistant to Other Drugs". U.S. Food and Drug Administration (FDA) (Press release). 23 November 2021. Archived from the original on 24 November 2021. Retrieved 23 November 2021. This article incorporates text from this source, which is in the public domain.

[SPS2022-4] "Maribavir". SPS - Specialist Pharmacy Service. 18 January 2017. Archived from the original on 5 March 2022. Retrieved 24 October 2022.

[5] "Maribavir". Goodrx. Archived from the original on 24 October 2022. Retrieved 24 October 2022.

[1]

[2]

[3]

[4]

[5]